Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AstraZeneca beats Street EPS

AstraZeneca (LSE:AZN; AZN) reported third quarter EPS of $0.55, beating by $0.02 the Street's $0.53 estimate and up 19%

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE